Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Fiche publication
Date publication
février 2020
Journal
Cardiovascular diabetology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LESSINGER Jean-Marc, Pr SCHINI-KERTH Valérie, Dr AUGER Cyril
Tous les auteurs :
Park SH, Farooq MA, Gaertner S, Bruckert C, Qureshi AW, Lee HH, Benrahla D, Pollet B, Stephan D, Ohlmann P, Lessinger JM, Mayoux E, Auger C, Morel O, Schini-Kerth VB
Lien Pubmed
Résumé
Empagliflozin (empa), a selective sodium-glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of glycemic control. The cardiovascular protective effect of empa was evaluated in an experimental model of metabolic syndrome, the obese ZSF1 rat, and its' lean control.
Mots clés
Empagliflozin, Endothelial function, Heart function, Heart structure, Metabolic syndrome, SGLT2, Senescence, ZSF1
Référence
Cardiovasc Diabetol. 2020 Feb 18;19(1):19